2022年世界肺癌大会（WCLC）将于8月6日至9日在奥地利首都维也纳展览会议中心盛大举行，作为世界上最大的肺癌和其他胸部恶性肿瘤会议，WCLC吸引着全球专家学者的目光，最新前沿进展令人目接不暇。日程目前已经公布，在口头报告专场，多位中国学者将汇报最新研究成果。【肿瘤资讯】带您抢先一览！
“Oral Session”的中国好声音
专场：OA02——From Locally Advanced to Unresectable NSCLC: Improvement of Multimodality Treatment
报告标题：OA02.05——Sugemalimab vs Placebo after cCRT or sCRT in pts with Unresectable Stage III NSCLC: Final PFS Analysis of a Phase 3 Study
演讲者：吴一龙 广东省人民医院
专场：OA03——Molecular Targeted Treatments
报告标题：OA03.07——Safety and Efficacy of D-1553 in Patients with KRAS G12C Mutated Non-Small Cell Lung Cancer: A Phase 1 Trial
演讲者：陆舜 上海交通大学附属胸科医院
专场：OA05——The Granularity of Lung Cancer Screening Implementation
报告标题：OA05.05——China Lung Cancer Screening (CLUS) Version 1.0: Mortality, Survival and Incidence Rates with Long-Term Follow-up
演讲者：钱芳菲 上海交通大学附属胸科医院
通讯作者：韩宝惠 上海交通大学附属胸科医院
专场：OA09——Precision Immunotherapy via Modulation of the Tumor Microenvironment
报告标题：OA09.03——Single Cell Analyses Reveal Effects of Immunosenescence Cells in Neoadjuvant Immunotherapy of Lung Squamous cell Carcinoma Patients
演讲者：Tao Wang
专场：OA11——Optimal Patient Selection for Local Therapy in Stage IV NSCLC
报告标题：OA11.05——Treatment Strategies Based on Different Oligoprogressive Patterns after Immunotherapy Resistance in Advanced NSCLC演讲者：陆舜 上海交通大学附属胸科医院
报告标题：OA11.06——Sequencing of ctDNA Revealed Radiotherapeutic Efficacy and Prognosis in Non-small Cell Lung Cancer Patients with Brain Metastasis演讲者：董晓荣 华中科技大学同济医学院附属协和医院
专场：OA13——Evolving Epidemiology of Lung Cancer Beyond Tobacco
报告标题：OA13.05——Lung Cancer Risk Prediction Nomogram in Chinese Female Non-smokers
演讲者：郭兰伟 河南省肿瘤医院
“Mini Oral Session”的中国好声音
专场：MA01——Molecular Subtypes and Prognostic Factors for SCLC and Neuroendocrine Tumors
报告专题：MA01.05——Immuno-microenvironment (TIME) Heterogeneity of Small Cell Lung Cancer (SCLC) Stratified by Molecular Subtypes
演讲者：Xujie Sun
专场：MA02——Molecular Underpinnings of Lung Cancer Histological Differentiation and Targeted Therapeutics
报告专题：MA02.05——Dynamic Mutation Profiles of SCLC Transformation in NSCLC Patients Harboring Concurrent EGFR/TP53/RB1 Mutations
演讲者： 黄婕 广东省人民医院
通讯作者： 吴一龙 广东省人民医院
专场：MA04——Pulmonology, Radiology, and Staging
报告专题：MA04.03——Reconsidering T Classification for T3/T4 Non-small Cell Lung Cancer with Additional Nodule(s)
演讲者：Fang Wang
报告专题：MA04.07——A Controlled Study of Pathological T- staging and Imaging T-staging of NSCLC Based on Artificial Intelligence
演讲者：Yuanyong Wang
专场：MA05——Immune Landscape and Molecular Profiling of Lung Cancer
报告专题：MA05.03——Utilization of Genomic Mutation Signature to Predict the Immunotherapy Response in Non-small Cell Lung Cancer
演讲者：Wenbin Li
报告专题：MA05.05——Analysis of CREBBP as a Potential Biomarker for Immune Checkpoint Therapy in Solid Tumors and Its Correlation With Immune Microenvironment
演讲者：Xiaoli Liu
报告专题：MA05.07——Intertumoral Molecular Heterogeneity of Non-small Cell Lung Cancer With MET Exon 14 Skipping
演讲者：Yuchen Han
专场：MA06——Resectable and Unresectable Locally Advanced Lung Cancer
报告专题：MA06.07——Molecular Typing of pN2 Lung Adenocarcinoma: A Retrospective Study Based on Transcriptome Sequencing
演讲者：Jianfei Zhu
报告专题：MA06.09——Deep Learning for Predicting MPR to Neoadjuvant Immunotherapy in NSCLC
演讲者：Yifan Zhong
专场：MA09——Palliative Radiotherapy: The Changing Landscape with Immunotherapy and Targeted Therapies
报告专题：MA09.04——First-line PD-1 Inhibitors and Chemotherapy Combined with or without Radiotherapy in Advanced Non-small-cell Lung Cancer
演讲者： 董晓荣 华中科技大学同济医学院附属协和医院
报告专题：MA09.08——Radiotherapy Improves Outcomes to Immunotherapy in Patients with Stage III and IV NSCLC
演讲者：Haihua Yang
专场：MA14——Palliative and Supportive Care—The Forgotten Trade
报告专题：MA14.05——A Double-blind Phase III Trial of Denosumab Biosimilar QL1206 vs Denosumab in Bone Metastatic Tumor: Lung Cancer Cohort Data
演讲者： 黄岩 中山大学附属肿瘤医院
通讯作者：张力 中山大学附属肿瘤医院
本文转自肿瘤资讯（由“抗癌管家网站-康爱管家”转载分享）
